Aug 2026· IEEE transactions on computational biology and bioinformatics· Vol PP· 0 citations
Medicine
TL;DR
SGTL-DDA is proposed, a novel graph transformer framework designed to incorporate structural information and domain-specific knowledge from heterogeneous biological information networks (HBINs) that successfully identifies both known therapeutics and novel repositioning candidates, supported by molecular docking results and literature evidence.
Abstract
Accurately predicting drug-disease associations (DDAs) is essential for accelerating the discovery of novel therapeutics. Graph representation learning-based computational models have become increasingly popular for this task due to their efficiency and cost-effectiveness. However, existing approaches often suffer from structural inductive biases and a limited ability to capture the rich heterogeneous context of biomedical molecules, which constrains their capacity to learn expressive drug and disease representations. To address this issue, we propose SGTL-DDA, a novel graph transformer framework designed to incorporate structural information and domain-specific knowledge from heterogeneous biological information networks (HBINs). SGTL-DDA integrates a meta-path-guided sampling strategy with a multi-level attention mechanism, enabling the model to jointly learn from both structural dependencies and attribute semantics in an end-to-end manner. Extensive experiments on two benchmark datasets demonstrate that SGTL-DDA consistently outperforms state-of-the-art methods in terms of Accuracy, F1-score, and AUC under a ten-fold cross-validation scheme. Furthermore, case studies on Alzheimer's disease and breast cancer confirm the predictive capability of SGTL-DDA, as it successfully identifies both known therapeutics and novel repositioning candidates, supported by molecular docking results and literature evidence.
KGDDA is proposed, a multimodal framework designed for drug-disease association prediction that synergistically integrates KGs with medical ontologies, enabling the adaptive capture of intricate drug-disease interactions.
Qi-Chang Zhao, Qiao Ling, Muhammad Habibulla Alamin et al.· IEEE Transactions on Computa...· 0 citations
VitaGraph is presented, a comprehensive multi-purpose biological knowledge graph built by integrating and refining multiple public datasets and enabling benchmarking of graph-based models and offering the opportunity to tackle tasks such as drug repurposing, PPI prediction, and side-effect prediction, among others.
Francesco Madeddu, Lucia Testa, Gianluca De Carlo et al.· Scientific Data· 0 citations
This work proposes GraphTransDTI, a synergistic hybrid framework that integrates a Graph Transformer to represent drug graph structures, a CNN-BiLSTM network to encode protein sequence context, and a Cross-Attention mechanism to model cross-domain interactions.
Vang V. Le, Mai Thi Anh Nhu, Pham Truong Viet Thong· PLoS ONE· 0 citations
Experiments demonstrate that HSAF-DDI achieves superior overall performance compared to state-of-the-art methods, indicating the critical role of fine-grained biological features in improving the DDI prediction performance.
Xiaoli Lin, Si-Yuan Zhang, Bo Li et al.· Journal of Chemical Informat...· 0 citations
Among class imbalance strategies tested, Tail-Aware Focal Loss outperforms standard cross-entropy by 3.1% on Macro F1 and 7.4% on Recall, striking a better balance between class performance than either weighted cross-entropy or weighted random sampling.
Varshini Venkatesh, V. G, Dhannya S. M.· Bioinformatics· 0 citations
IHLO-DTI, a novel prediction model based on an improved hypergraph neural network and Laplacian matrix optimization, can effectively capture high-order many-to-many interactions between drugs and targets, improving prediction accuracy and robustness.
Guolongwei Dai, Tao Luo, Dan-Dan Li et al.· ACS Synthetic Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.